Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.76 -11.1%	$16.34	$9.57 ▼ $29.86	$2.60B	0.93	1.58 million shs	3.01 million shs
DNTH Dianthus Therapeutics	$20.40 +0.2%	$18.61	$13.37 ▼ $32.27	$654.46M	1.38	272,921 shs	494,633 shs
IBRX ImmunityBio	$2.75 -2.8%	$2.79	$1.83 ▼ $7.48	$2.50B	0.08	6.36 million shs	7.05 million shs
OGN Organon & Co.	$9.46 -1.9%	$9.52	$8.01 ▼ $23.10	$2.51B	0.6	3.62 million shs	3.13 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-11.09%	-8.47%	+7.30%	+49.11%	-40.19%
DNTH Dianthus Therapeutics	+0.25%	+1.69%	+16.97%	+4.62%	-26.30%
IBRX ImmunityBio	-2.83%	-2.14%	-3.17%	+11.34%	-55.14%
OGN Organon & Co.	-1.90%	-4.83%	-4.31%	-14.84%	-55.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.8394 of 5 stars	3.4	2.0	0.0	3.4	3.6	1.7	0.0
DNTH Dianthus Therapeutics	1.1306 of 5 stars	3.6	0.0	0.0	0.0	1.4	0.8	0.0
IBRX ImmunityBio	2.2825 of 5 stars	3.6	1.0	0.0	0.0	2.7	1.7	0.6
OGN Organon & Co.	4.8555 of 5 stars	3.3	3.0	1.7	3.7	2.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.83% Upside
DNTH Dianthus Therapeutics	3.13	Buy	$53.00	159.80% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	345.45% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	90.27% Upside

Current Analyst Ratings Breakdown

Latest DNTH, ARWR, IBRX, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	651.99	N/A	N/A	$1.54 per share	10.88
DNTH Dianthus Therapeutics	$6.24M	105.14	N/A	N/A	$11.91 per share	1.71
IBRX ImmunityBio	$14.74M	164.67	N/A	N/A	($0.57) per share	-4.82
OGN Organon & Co.	$6.40B	0.38	$4.83 per share	1.96	$1.83 per share	5.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	22.17	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$2.88	N/A	N/A	N/A	-1,544.23%	-29.26%	-27.87%	8/6/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.28	2.53	1.00	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest DNTH, ARWR, IBRX, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	IBRX ImmunityBio	-$0.10	N/A	N/A	N/A	$21.95 million	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.93	N/A	N/A	N/A	$1.55 billion	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.78%	N/A

Latest DNTH, ARWR, IBRX, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
DNTH Dianthus Therapeutics	N/A	15.98	15.99
IBRX ImmunityBio	N/A	2.22	2.05
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
DNTH Dianthus Therapeutics	47.53%
IBRX ImmunityBio	8.58%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
DNTH Dianthus Therapeutics	8.15%
IBRX ImmunityBio	76.79%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	29.54 million	Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable

DNTH, ARWR, IBRX, and OGN Headlines

Recent News About These Companies

TUESDAY INVESTOR DEADLINE: Organon & Co. ...

3 hours ago | gurufocus.com

TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

4 hours ago | prnewswire.com

Organon (OGN) Registers a Bigger Fall Than the Market: Important Facts to Note

July 18 at 6:51 PM | zacks.com

ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co. - OGN

July 18 at 6:00 PM | businesswire.com

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July ...

July 18 at 5:01 PM | gurufocus.com

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July 22, 2025 Deadline to file Lead Plaintiff Motion

July 18 at 4:46 PM | globenewswire.com

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy ...

July 18 at 12:08 PM | gurufocus.com

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

July 18 at 12:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN

July 18 at 12:00 PM | globenewswire.com

Hussman Strategic Advisors Inc. Sells 84,000 Shares of Organon & Co. (NYSE:OGN)

July 18 at 10:39 AM | marketbeat.com

OGN SECURITIES FRAUD: Organon & Co. (NYSE:OGN) 27% Stock Drop Triggers Class Action Lawsuit ...

July 18 at 10:31 AM | gurufocus.com

Levi & Korsinsky Notifies Shareholders of Organon & Co. ...

July 18 at 9:31 AM | gurufocus.com

OGN SECURITIES FRAUD: Organon & Co. (NYSE:OGN) 27% Stock Drop Triggers Class Action Lawsuit – Contact BFA Law by July 22 Legal Deadline

July 18 at 9:07 AM | globenewswire.com

Levi & Korsinsky Notifies Shareholders of Organon & Co.(OGN) of a Class Action Lawsuit and an Upcoming Deadline

July 18 at 8:45 AM | prnewswire.com

Shareholders that lost money on Organon & Co.(OGN) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

July 17 at 4:14 PM | globenewswire.com

OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 17 at 4:00 PM | globenewswire.com

OGN Deadline: OGN Investors with Losses in Excess of $100K Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

July 17 at 3:11 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

July 17 at 10:00 AM | prnewswire.com

The Gross Law Firm Reminds Organon & Co. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGN

July 17 at 9:00 AM | prnewswire.com

Easterly Investment Partners LLC Has $7.25 Million Holdings in Organon & Co. (NYSE:OGN)

July 17 at 8:47 AM | marketbeat.com

Organon & Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

July 17 at 8:21 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH, ARWR, IBRX, and OGN Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.76 -2.09 (-11.09%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$16.86 +0.10 (+0.60%)

As of 07/18/2025 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Dianthus Therapeutics NASDAQ:DNTH

$20.40 +0.05 (+0.25%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$20.40 0.00 (-0.02%)

As of 07/18/2025 04:04 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

ImmunityBio NASDAQ:IBRX

$2.75 -0.08 (-2.83%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.76 +0.01 (+0.22%)

As of 07/18/2025 08:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Organon & Co. NYSE:OGN

$9.46 -0.18 (-1.87%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$9.47 +0.01 (+0.10%)

As of 07/18/2025 07:56 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time